Clinical Trial Alert – February 2020
Cystic Fibrosis Foundation issued the following clinical trial alert in February.
February 25, 2020
Description: This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
Age: 18 Years and Older
Mutation: No Mutation Requirement
Fev1% Predicted: 40 to 90%
Number of Visits: 6
Length of Participation: 2 months
ClinicalTrial.gov link: https://clinicaltrials.gov/ct2/show/NCT04279769